

DAFTAR PUSTAKA

- Abbas, A., Lichtman, A. and Pillai, S. (2014), *Cellular and Molecular Immunology*, Saunder Elsevier, Philadelphia.
- Abbas, A., Lichtman, A. and Pillai, S. (2019), *Basic Immunology E-Book: Functions and Disorders of the Immune System*, 5th ed., Elsevier, Philadelphia.
- Afina, N.N., Olivianto, E. and Sujuti, H. (2014), “Kadar C-Reactive Protein (CRP) Serum sebagai Pertanda Prognosis pada Pasien Pneumonia Anak”, *Majalah Kesehatan FKUB*, Vol. 1 No. 3, pp. 125–129.
- Ahnach, M., Zbiri, S., Nejari, S., Ousti, F. and Elkettani, C. (2020), “C-reactive protein as an early predictor of COVID-19 severity”, *J Med Biochem*, Vol. 39 No. 4, pp. 500–507.
- Aksel, G., İslam, M.M., Algin, A., Eroğlu, S.E., Yaşar, G.B., Ademoğlu, E. and Dölek, Ü.C. (2021), “Early predictors of mortality for moderate to severely ill patients with Covid-19”, *Am J Emerg Med*, Vol. 45 No. June 2020, pp. 290–296.
- Asghar, M.S., Khan, N.A., Haider Kazmi, S.J., Ahmed, A., Hassan, M., Jawed, R., Akram, M., *et al.* (2020), “Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis”, *J Community Hosp Intern. Med. Perspect*, Vol. 10 No. 6, pp. 514–520.
- Bergantini, L., Bargagli, E., D’Alessandro, M., Refini, R.M., Cameli, P., Galasso, L., Scapellato, C., *et al.* (2021), “Prognostic bioindicators in severe COVID-19 patients”, *Cytokine*, Vol. 141 No. January, p. 155455.
- Bikdeli, B., Madhavan, M. V., Gupta, A., Jimenez, D., Burton, J.R., Der Nigoghossian, C., Chuich, T., *et al.* (2020), “Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research”, *J Thromb Haemost*, Vol. 120 No. 7, pp. 1004–1024.
- BNPB. (2020), “Peta Sebaran Covid di Indonesia”, available at: www.Covid.go.id (accessed 20 September 2021).
- Çakırca, D.T., Torun, A., Çakırca, G. and Portakal, R.D. (2021), “Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia”, *Int J Clin.*
- Cao, W. and Li, T. (2020), “COVID-19: towards understanding of pathogenesis”, *Cell Research*, Springer US, Vol. 30 No. 5, pp. 367–369.
- Carlos, W.G., Cruz, C.S. Dela, Cao, B., Pasnick, S. and Jamil, S. (2020), “COVID-19 Disease due to SARS-CoV-2 (Novel Coronavirus)”, *Am J Respir Crit Care Med*, Vol. 201 No. 4, pp. P7–P8.
- Cevik, M., Kuppalli, K., Kindrachuk, J. and Peiris, M. (2020), “Virology , transmission , and

pathogenesis of SARS-CoV-2”, *BMJ*, Vol. 2019, pp. 1–6.

- Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K. and Perlman, S. (2016), “Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice”, *Cell Host Microbe*, Vol. 19 No. 2, pp. 181–193.
- Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., *et al.* (2020), “Clinical and immunological features of severe and moderate coronavirus disease 2019”, *J Clin Invest*, Vol. 130 No. 5, pp. 2620–2629.
- Chen, N., Min, Z., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., *et al.* (2020), “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Nanshan”, *Lancet*, Vol. 395 No. January, pp. 507–513.
- Chen, R., Wang, L., Zhao, Q., Li, Z., Chen, M., Lian, G. and Zhang, J. (2021), “Platelet-to-lymphocyte ratio and C-reactive protein as markers for colorectal polyp histological type”, *BMC Cancer*, Vol. 21 No. 1, pp. 1–8.
- Delshad, M., Tavakolinia, N., Pourbagheri-Sigaroodi, A., Safaroghli-Azar, A., Bagheri, N. and Bashash, D. (2021), “The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19”, *Int Immunopharmacol*, Vol. 95 No. January.
- Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., *et al.* (2020), “Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)”, *Front Immunol*, Vol. 11 No. May, pp. 1–7.
- Doremalen, van N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N., Tamin, A., *et al.* (2020), “Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1”, *N Engl J Med*, Vol. 382 No. 16, pp. 1564–1567.
- Eastwood, B.J., Farmen, M.W., Iversen, P.W., Craft, T.J., Smallwood, J.K., Garbison, K.E., Delapp, N.W., *et al.* (2006), “The minimum significant ratio: A statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies”, *J Biomol Screen*, Vol. 11 No. 3, pp. 253–261.
- Elshazli, R., Toraih, E., Elgaml, A., El-Mowafy, M., El-Mesery, M., Amin, M., Hussein, M., *et al.* (2020), “Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients”, *PloS One*, Vol. 15 No. 8.
- Engelmann, B. and Massberg, S. (2013), “Thrombosis as an intravascular effector of innate immunity”, *Nat Rev Immunol*, Vol. 13 No. 1, pp. 34–45.
- Frater, J.L., Zini, G., D’Onofrio, G. and Rogers, H.J. (2020), “COVID-19 and the clinical hematology laboratory”, *Int J Lab Hematol*, No. 2, pp. 0–3.
- Fu, H., Qin, B., Hu, Z., Ma, N., Yang, M., Wei, T., Tang, Q., *et al.* (2015), “Neutrophil- and

- platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis”, *Clin Lab*, Vol. 61 No. 3–4, pp. 269–273.
- Fuji, T., Fujita, S., Kawai, Y., Nakamura, M., Kimura, T., Fukuzawa, M., Abe, K., *et al.* (2015), “Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V”, *Thromb J*, Vol. 13 No. 1, pp. 1–9.
- Gasparyan, A.Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M. and Kitas, G.D. (2019), “The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases”, *Ann Lab Med*, Vol. 39 No. 4, pp. 345–357.
- Gugus Tugas Percepatan Penanganan COVID-19. (2020), “Protokol Percepatan Penanganan Pandemi Covid-19 (Corona Virus Disease 2019)”, *Gugus Tugas Percepatan Penanganan COVID-19*, Vol. 19, p. 31.
- Hashem, M.K., Khedr, E.M., Daef, E., Mohamed-Hussein, A., Mostafa, E.F., Hassany, S.M., Galal, H., *et al.* (2021), “Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer”, *Egypt J Bronchol*, Vol. 15 No. 1.
- He, S., Liu, W., Jiang, M., Huang, P., Xiang, Z., Deng, D., Chen, P., *et al.* (2021), “Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study”, *PLoS ONE*, Vol. 16 No. 4, pp. 1–12.
- Holinstat, M. (2017), “Normal platelet function”, *Cancer Metastasis Rev*, Vol. 36 No. 2, pp. 195–198.
- Hu, B., Huang, S. and Yin, L. (2021), “The cytokine storm and COVID-19”, *J Med Virol*, Vol. 93 No. 1, pp. 250–256.
- Jiang, Y., Wei, X., Guan, J., Qin, S., Wang, Z. and Lu, H. (2020), “COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential”, *J Clin Immunol*.
- Jose, R.J. and Manuel, A. (2020), “COVID-19 cytokine storm: the interplay between inflammation and coagulation”, *Lancet Respir Med*, Vol. 8 No. 6, pp. e46–e47.
- Julianti, I. (2018), “Pemeriksaan Kadar Darah Rutin Menggunakan Hematology Analyzer”, *Universitas Indonesia*, pp. 6–7.
- Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E.J., Armistead, I., *et al.* (2021), “Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)”, *Arch Clin Infect Dis*, Vol. 72 No. 9, pp. e206–e214.
- Kuba, K., Imai, Y., Ohto-Nakanishi, T. and Penninger, J.M. (2010), “Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters”, *Pharmacol Ther*, Vol. 128 No. 1, pp. 119–128.

- Kurniawan, L.B. (2014), “Konfirmasi Apusan Darah Tepi untuk Pseudotrombositopenia”, *Cdk Journal*, Vol. 41 No. 6, pp. 422–424.
- Kusuma, G.F.P., Maliawan, S., Gde, T., Mahadewa, B., Gde, T. and Senapathi, A. (2020), “Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio Correlations with C-reactive Protein and Erythrocyte Sedimentation Rate in Traumatic Brain Injury”, *J. Med. Sci*, Vol. 8, pp. 1185–1192.
- Lang, Z.W., Zhang, L.J., Zhang, S.J., Meng, X., Li, J.Q., Song, C.Z., Sun, L., *et al.* (2003), “A clinicopathological study of three cases of severe acute respiratory syndrome (SARS)”, *Pathology*, Vol. 35 No. 6, pp. 526–531.
- Lardinois, B., Favresse, J., Chatelain, B., Lippi, G. and Mullier, F. (2021), “Pseudothrombocytopenia—a review on causes, occurrence and clinical implications”, *J Clin Med*, Vol. 10 No. 4, pp. 1–19.
- Leick, M., Azcutia, V., Newton, G. and Luscinskas, F.W. (2014), “Leukocyte recruitment in inflammation: Basic concepts and new mechanistic insights based on new models and microscopic imaging technologies”, *Cell Tissue Res*, Vol. 355 No. 3, pp. 647–656.
- Lestari, N.A. and Retnoningrum, D. (2021), “Correlation between Platelet to Lymphocyte Ratio with C-Reactive Protein in COVID-19 Patients”, *Indones J Clinical Pathol Med Laboratory*, Vol. 28 No. 1, pp. 17–21.
- Li, P., Xia, C., Liu, P., Peng, Z., Huang, H., Wu, J. and He, Z. (2020), “Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD)”, *BMC Nephrology*, pp. 1–8.
- Liu, F., Li, L., Xu, M. Da, Wu, J., Luo, D., Zhu, Y.S., Li, B.X., *et al.* (2020), “Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19”, *J Clin Virol*, Elsevier, Vol. 127 No. April, p. 104370.
- Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., *et al.* (2020), “Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients”, *EBioMedicine*, Vol. 55.
- Martínez-Pizarro, S. (2020), “Renin-angiotensin system inhibitors in patients with COVID-19”, *Revista Cubana de Cardiología y Cirugía Cardiovascular*, Vol. 26 No. 2, pp. 1–2.
- Merad, M. and Martin, J.C. (2020), “Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages”, *Nature Reviews Immunology*, Springer US, Vol. 20 No. 6, pp. 355–362.
- Mo, H., Zeng, G., Ren, X., Li, H., Ke, C., Tan, Y., Cai, C., *et al.* (2006), “Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance”, *Respirology*, Vol. 11 No. 1, pp. 49–53.
- Mousavi, S.A., Rad, S., Rostami, T., Rostami, M., Mousavi, S.A., Mirhoseini, S.A. and Kiumarsi, A. (2020), “Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study”, *Hematology*.

- Mubarik, S., Liu, X., Eshak, E.S., Liu, K. and Liu, Q. (2021), "The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan , China : A Multicenter Retrospective Cohort Study", *Front Med*, Vol. 8 No. May.
- Nar, R. and Emekli, D.I. (2017), "The Evaluation of Analytical Performance of Immunoassay Tests by Using Six-Sigma Method", *Journal of Medical Biochemistry*, Vol. 36 No. 4, pp. 301–308.
- Newling, M., Sritharan, L., van der Ham, A.J., Hoepel, W., Fiechter, R.H., de Boer, L., Zaat, S.A.J., *et al.* (2019), "C-Reactive Protein Promotes Inflammation through FcγR-Induced Glycolytic Reprogramming of Human Macrophages", *J Immunol*, Vol. 203 No. 1, pp. 225–235.
- Onder, G., Rezza, G. and Brusaferro, S. (2020), "Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy", *JAMA*, Vol. 323 No. 18, pp. 1775–1776.
- Ong, S.W.X., Tan, Y.K., Chia, P.Y., Lee, T.H., Ng, O.T., Wong, M.S.Y. and Marimuthu, K. (2020), "Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from a Symptomatic Patient", *JAMA*, Vol. 323 No. 16, pp. 1610–1612.
- PDS PatKLIn. (2020), "Panduan Tata Laksana Pemeriksaan Rapid test antigen", *PDS PatKLIn*, pp. 1–11.
- Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., Losi, G., Dacrema, A., Nuccetelli, M., *et al.* (2020), "Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients", *Clin Chim Acta*, Vol. 509 No. June, pp. 135–138.
- Porte, L., Legarraga, P., Vollrath, V. and Aguilera, X. (2020), "Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples", *Int j Infect Dis*, Vol. 99 No. January, pp. 328–333.
- Prasetya, I.B., Cucunawangsih, Lorens, J.O., Sungono, V., El-Khobar, K.E. and Wijaya, R.S. (2021), "Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia", *Clin Epidemiology Glob Health*, Vol. 11 No. June, p. 100803.
- Promptchara, E., Ketloy, C. and Palaga, T. (2020), "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic", *Asian Pacific Journal of Allergy and Immunology*, Vol. 38 No. 1, pp. 1–9.
- Pyzdek, T. (2009), *The Six Sigma Handbook Chapter 1, Search*.
- Qu, R., Ling, Y., Zhang, Y. hui zhi, Wei, L., Chen, X., Li, X. mian, Liu, X., *et al.* (2020), "Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19", *J Med Virol*.
- Rayes, J., Bourne, J.H., Brill, A. and Watson, S.P. (2020), "The dual role of platelet-innate immune cell interactions in thrombo-inflammation", *Res Pract Thromb Haemost*, Vol. 4

No. 1, pp. 23–35.

- Samuels, T.H.A., Wyss, R., Ongarello, S., Moore, D.A.J., Schumacher, S.G. and Denking, C.M. (2021), “Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis”, *PLoS ONE*, Vol. 16 No. 7 July, pp. 1–15.
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K. and Desai, P. (2020), “Comorbidity and its Impact on Patients with COVID-19”, *SN Compr Clin Med*.
- Sarkar, S., Kannan, S., Khanna, P. and Singh, A.K. (2021), “Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis”, *J Med Virol*, Vol. 94, p. 211–221.
- Semple, J.W., Italiano, J.E. and Freedman, J. (2011), “Platelets and the immune continuum”, *Nature Reviews Immunology*, Vol. 11 No. 4, pp. 264–274.
- Setyowatie, L., Sukanto, H. and Murtiastutik, D. (2016), “C-Reactive Protein pada Berbagai Derajat Keparahan Psoriasis Vulgaris”, *Berk Ilmu Kesehat Kulit Kelamin*, Vol. 28 No. 2, pp. 1–9.
- Seyit, M., Avci, E., Nar, R., Senol, H., Yilmaz, A., Ozen, M., Oskay, A., *et al.* (2020), “Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19”, *Am J Emerg Med*.
- Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., Bucci, E., *et al.* (2020), “COVID-19 infection: the perspectives on immune responses”, *Cell Death Differ*, Vol. 27 No. 5, pp. 1451–1454.
- Simadibrata, D.M., Adi, B. and Pandhita, W. (2020), “Platelet-to-lymphocyte ratio , a novel biomarker to predict the severity of COVID-19 patients : A systematic review and meta-analysis”, *J Intensive Care Soc*, No. Vi.
- Slota, A.A., Malik, D. and Hall, D. (2020), “Pseudo-Thrombocytosis Caused by Extreme Microcytosis in a Patient with Alpha Thalassemia Trait”, *Indian J Hematol Blood Transfus*, Springer India, Vol. 36 No. 4, pp. 779–780.
- Smilowitz, N.R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J.S. and Berger, J.S. (2021), “C-reactive protein predicts outcome in COVID-19”, *Eur Heart J*, Vol. 42 No. 23, pp. 2280–2283.
- Sproston, N.R. and Ashworth, J.J. (2018), “Role of C-reactive protein at sites of inflammation and infection”, *Front Immunol*, Vol. 9 No. APR, pp. 1–11.
- Sun, S., Cai, X., Wang, H., Hed, G., Line, Y., Lue, B., Chene, C., *et al.* (2020), “Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China”, *Clin Chim Acta*, Vol. 507 No. January, pp. 174–180.
- Susilo, A., Rumende, C.M., Pitoyo, C.W., Santoso, W.D., Yulianti, M., Herikurniawan, H., Sinto, R., *et al.* (2020), “Coronavirus Disease 2019: Tinjauan Literatur Terkini”, *J*

Penyakit Dalam Indones, Vol. 7 No. 1, p. 45.

- Tan, L., Wang, Q., Zhang, D., Ding, J., Huang, Q., Tang, Y.Q., Wang, Q., *et al.* (2020), “Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study”, *Signal Transduc Target Ther*, Vol. 5 No. 1, pp. 16–18.
- Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A. and Ng, L.F.P. (2020), “The trinity of COVID-19: immunity, inflammation and intervention”, *Cell Host Microbe*, Vol. 20 No. 6, pp. 363–374.
- Thachil, J., Cushman, M. and Srivastava, A. (2020), “A proposal for staging COVID-19 coagulopathy”, *Res Pract Thromb Haemost*, Vol. 4 No. 5, pp. 731–736.
- Toledo, S.L. de O., Nogueiraa, L.S., Carvalho, M. das G., Rios, D.R.A. and Pinheiro, M. de B. (2020), “SCoVID-19: Review and hematologic impact Silvia”, *Clin Chim Acta*, Vol. 510 No. January, pp. 170–176.
- Tóth, J., Oláh, A. V., Petercsák, T., Kovács, T. and Kappelmayer, J. (2020), “Detection of haemolysis, a frequent preanalytical problem in the serum of newborns and adults”, *Electron J Int Fed Clin Chem*, Vol. 31 No. 1, pp. 6–14.
- Utama, I.M.G.D.L. (2016), “Uji Diagnostik C-Reactive Protein, Leukosit, Nilai Total Neutrofil dan Suhu Anak Demam dengan Penyebab yang Tidak Diketahui”, *Sari Pediatri*, Vol. 13 No. 6, p. 412.
- V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. and Thiel, V. (2021), “Coronavirus biology and replication: implications for SARS-CoV-2”, *Nat Rev Microbiol*, Vol. 19 No. 3, pp. 155–170.
- Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer, M.A. and Solomon, S.D.T. (2020), “Renin – Angiotensin – Aldosterone System Inhibitors in Patients with Covid-19”, *N Engl J Med*, Vol. 382 No. 17, pp. 1653–1659.
- Wang, Tang and Wei. (2020), “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China”, *J Med Virol*, Vol. 92 No. 4, pp. 441–447.
- Waris, A., Din, M., Khalid, A., Lail, R.A., Shaheen, A., Khan, N., Nawaz, M., *et al.* (2021), “Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan’s experience”, *J Clin Lab Anal*, Vol. 35 No. 6, p. e23809.
- WHO. (2020a), “Corona virus (covid 19) Dashboard”, *Wold Health Organization*, available at: <https://covid19.who.int/> (accessed 20 September 2021).
- WHO. (2020b), “Clinical management of COVID-19: interim guidance”, *Clinical Management of COVID-19: Interim Guidance*, 1st ed., WHO, Jenewa, pp. 13–17.
- Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D., *et al.* (2020), “Virological assessment of hospitalized patients with COVID-2019”, *Nature*, Vol. 581 No. 7809, pp. 465–469.
- Wolff, D., Nee, S., Hickey, N.S. and Marschollek, M. (2021), “Risk factors for Covid-19

- severity and fatality: a structured literature review”, *Infection*, Springer Berlin Heidelberg, Vol. 49 No. 1, pp. 15–28.
- Wool, G.D. and Miller, J.L. (2021), “The Impact of COVID-19 Disease on Platelets and Coagulation”, *Pathobiology*, Vol. 60637 No. 88, pp. 15–27.
- Wu F, Wang, A Liu, M Wang, Q Chen, J Xia, Sl.Yz.Yx.Jl.Lj.Sl.Hw.Yh. (2020), “Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications”, *SSRN Journal*.
- Wu, Z. and McGoogan, J.M. (2020), “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention”, *JAMA*, Vol. 323 No. 13, pp. 1239–1242.
- Yang, A.-P., Liu, J., Tao, W. and Li, H. (2020a), “The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients”, *International Immunopharmacology*, Elsevier, Vol. 84, p. 106504.
- Yang, A., Liu, J., Tao, W. and Li, H. (2020b), “The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients”, *Int Immunopharmacol*, Vol. 84 No. January.
- Yao, C.Y., Liu, X.L. and Tang, Z. (2017), “Prognostic role of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio for hospital mortality in patients with AECOPD”, *Int J Chron Obstruct Pulmon Dis*, Vol. 12, pp. 2285–2290.
- Yatim, N., Boussier, J., Chocron, R., Hadjadj, J., Philippe, A., Azoulay, C., Khider, L., *et al.* (2021), “Platelet activation in critically ill COVID - 19 patients”, *Ann of Intensive Care*, pp. 1–12.
- Yuksel, O.H., Urkmez, A., Akan, S., Yldirim, C. and Verit, A. (2015), “Predictive value of the platelet-to-lymphocyte ratio in diagnosis of prostate cancer”, *Asian Pac J Cancer Prev*, Vol. 16 No. 15, pp. 6407–6412.
- Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y. and Zuo, W. (2020), “Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2”, *American Journal of Respiratory and Critical Care Medicine*, Vol. 202 No. 5, pp. 756–759.
- Zu, Z.Y., Jiang, M. Di, Xu, P.P., Chen, W., Ni, Q.Q., Lu, G.M. and Zhang, L.J. (2020), “Coronavirus disease 2019 (Covid-19): A perspective from China”, *Radiology*, Vol. 296, pp. E15–E25.